Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma

Tae‐Young Na, Young Kee Shin, Kyung Jin Roh, Shin‐Ae Kang, Il Hong, Sae Jin Oh, Je Kyung Seong, Cheol Keun Park, Yoon La Choi, Mi‐Ock Lee – 27 March 2009 – Although hepatitis B virus X protein (HBx) has been implicated in abnormal lipid metabolism in hepatitis B virus (HBV)–associated hepatic steatosis, its underlying molecular mechanism remains unclear. Liver X receptor (LXR) plays an important role in regulating the expression of genes involved in hepatic lipogenesis. Here we demonstrate that LXRα and LXRβ mediate HBV‐associated hepatic steatosis.

Blockade of four‐transmembrane L6 family member 5 (TM4SF5)‐mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative

Sin‐Ae Lee, Hyung Won Ryu, Young Mee Kim, Suyong Choi, Mi Ji Lee, Tae Kyoung Kwak, Hyeon Jung Kim, Moonjae Cho, Ki Hun Park, Jung Weon Lee – 27 March 2009 – We previously reported that the four‐transmembrane L6 family member 5 (TM4SF5) was highly expressed in hepatocarcinoma, induced morphological elongation and epithelial‐mesenchymal transition, and caused abnormal cell growth in multilayers in vitro and tumor formation in vivo.

Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma

Shunsuke Ura, Masao Honda, Taro Yamashita, Teruyuki Ueda, Hajime Takatori, Ryuhei Nishino, Hajime Sunakozaka, Yoshio Sakai, Katsuhisa Horimoto, Shuichi Kaneko – 27 March 2009 – MicroRNA (miRNA) plays an important role in the pathology of various diseases, including infection and cancer.

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

Marc Mejias, Ester Garcia‐Pras, Carolina Tiani, Rosa Miquel, Jaime Bosch, Mercedes Fernandez – 27 March 2009 – Portal hypertension, the most important complication in patients with cirrhosis of the liver, is a serious and life‐threatening disease for which there are few therapeutic options.

A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature

Jean‐Louis Delaunay, Anne‐Marie Durand‐Schneider, Danièle Delautier, Alegna Rada, Julien Gautherot, Emmanuel Jacquemin, Tounsia Aït‐Slimane, Michèle Maurice – 27 March 2009 – Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease characterized by early onset of cholestasis that leads to cirrhosis and liver failure before adulthood. PFIC3 may be improved by chronic administration of ursodeoxycholic acid, although in many cases liver transplantation is the only therapy.

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

Rami Moucari, Vincent Mackiewicz, Olivier Lada, Marie‐Pierre Ripault, Corinne Castelnau, Michelle Martinot‐Peignoux, Agnes Dauvergne, Tarik Asselah, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Marie‐Hélène Nicolas‐Chanoine, Patrick Marcellin – 27 March 2009 – Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders.

Subscribe to